The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Open accessAbstract
BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial of unresectable hepatocellular carcinoma. METHODS: In this global, open-label, phase 3 trial, the majority of the patients we enrolled with unresectable hepatocellular carcinoma and no previous systemic treatment were randomly assigned to receive one of three regimens: tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE), durvalumab (1500 mg every 4 weeks), or sorafenib (400 mg twice daily). The primary objective was overall survival for STRIDE versus sorafenib. Noninferiority for overall survival for durvalumab versus sorafenib was a secondary objective. RESULTS: In total, 1171 patients were randomly assigned to STRIDE (n=393), durvalumab (n=389), or sorafenib (n=389). The median overall survival was 16.43 months (95% confidence interval [CI], 14.16 to 19.58) with STRIDE, 16.56 months (95% CI, 14.06 to 19.12) with durvalumab, and 13.77 months (95% CI, 12.25 to 16.13) with sorafenib. Overall survival at 36 months was 30.7%, 24.7%, and 20.2%, respectively. The overall survival hazard ratio for STRIDE versus sorafenib was 0.78 (96.02% CI, 0.65 to 0.93; P=0.0035). Overall survival with durvalumab monotherapy was noninferior to sorafenib (hazard ratio, 0.86; 95.67% CI, 0.73 to 1.03; noninferiority margin, 1.08). Median progression-free survival was not significantly different among all three groups. Grade 3/4 treatment-emergent adverse events occurred for 50.5% of patients with STRIDE, 37.1% with durvalumab, and 52.4% with sorafenib. CONCLUSIONS: STRIDE significantly improved overall survival versus sorafenib. Durvalumab monotherapy was noninferior to sorafenib for patients with unresectable hepatocellular carcinoma. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT03298451.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The response rate was 20% with durvalumab plus tremelimumab and 30% with atezolizumab plus bevacizumab, with median duration of response ranging from 18 months to 22 months.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-L1 inhibitor-based regimens received approvals in 2020 (atezolizumab plus bevacizumab) and 2022 (tremelimumab plus durvalumab) as first-line treatment options for unresectable hepatocellular carcinoma after showing improved outcomes over sorafenib, with median overall survival ranging from 16 months to 19 months.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the introduction of PD-L1 inhibitors in this setting, survival benefits versus sorafenib were improved with a median overall survival of 19•2 months with atezolizumab plus bevacizumab, 9,10 16•6 months with durvalumab monotherapy, and 16•4 months with tremelimumab plus durvalumab, 7,8 leading to regulatory”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At the RP2D, the safety profile was consistent with the known safety profile of durvalumab in combination with tremelimumab in adult patients (13, 14), and no new safety signals were identified in our pediatric population.”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“durvalumab plus tremelimumab has demonstrated improved OS compared with sorafenib alone in adults with unresectable hepatocellular cancer (14).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“In HIMALAYA, durvalumab plus tremelimumab yielded an objective response rate of 20% and median duration of response of 22•3 months.7”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“up to 20% of OBIs may be negative for both HBsAg and hepatitis B core antibody (anti-HBc) with existing assays [67, 68]”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,001
Systemic Therapies for Hepatocellular Carcinoma in India
Jahagirdar, V., Rama, K., Habeeb, M., Sharma, M., Rao, P. N., Reddy, D. N., Singal, A. G., & Kulkarni, A. V. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101440 · Cited by 9
Moriguchi, M., Okuda, K., Horiguchi, G., Kataoka, S., Seko, Y., Yamaguchi, K., Nishimura, T., Fujii, H., Mitsumoto, Y., Miyagawa, M., et al. (2024) · Liver International · doi:10.1111/liv.15918 · Cited by 9
Salani, F., Genovesi, V., Vivaldi, C., Massa, V., Cesario, S., Bernardini, L., Caccese, M., Graziani, J., Berra, D., Fornaro, L., et al. (2022) · Cancers · doi:10.3390/cancers14194896 · Cited by 10
“In the newly published randomized Himalaya trial (that will be discussed later), the results of the first-line therapy with the anti-PDL1 durvalumab are in line with those of nivolumab and pembrolizumab [10].”
BackgroundResultLi, L., Liu, H.-T., Teng, Y., Deng, Z., Zhang, G.-L., Su, J., Ma, L., & Zhong, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2151891 · Cited by 9
“Most recently, the STRIDE regimen (T300 mg + D1500 mg) demonstrated a statistically significant improvement in overall survival versus sorafenib in the HIMALAYA trial [80].”
BackgroundSantarsiero, A., Pappalardo, I., Rosa, G. M., Pisano, I., Superchi, S., Convertini, P., Todisco, S., Scafato, P., & Infantino, V. (2022) · Biomedicines · doi:10.3390/biomedicines10123120 · Cited by 9
“At present, the regimens Atezolizumab + Bevacizumab and Durvalumab/Tremelimumab represent the first immune combination therapies more effective than Sorafenib in the treatment of advanced HCC [8,9].”
BackgroundIssue on combined locoregional and systemic treatment for hepatocellular carcinoma
Wu, Y., Wakil, A., Salomon, F., & Pyrsopoulos, N. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2022.37 · Cited by 9
Song, X., Kelley, R. K., GREEN, M. L., Standifer, N. E., Lim, K., Zhou, D., Dunyak, J., Negro, A., Kurland, J. F., Ren, S., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2992 · Cited by 9
“This, combined with the saturable effects described in the model, provided a mechanistic framework for why a single priming dose of tremelimumab 300 mg in the STRIDE regimen is sufficient to drive improved efficacy outcomes through initial expansion of CD4+ Ki67+ and CD8+ Ki67+ T cells, while minimizing the AEs associ…”
BackgroundSelf-citationTada, F., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02026-2 · Cited by 9
“…anti-VEGF, were reported (HIMALAYA trial), with a comparison of Dur/Tre and sorafenib showing mOS of 16.43 vs. 13.77 months (HR 0.90, 95% CI 0.77–1.05) and mPFS of 3.78 vs. 4.07 months (HR 0.90, 95% CI 0.77–1.05) [44], while similar strategies have also been proposed by Llovet [45] and Finn [46].”
MethodInfluentialKudo, M. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-122 · Cited by 8
“Another point to note is that this guideline was published in 2021 and thus did not reflect the results of the HIMALAYA trial presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (4).”
ResultSelf-citationChen, B., Liang, P., Shih, T. T., Liu, T., Shen, Y., Lu, L., Lin, Z., Hsu, C., Hsu, C., Cheng, A., et al. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s462470 · Cited by 8
Self-citationAdvances in the management of complications from cirrhosis
Singh, J., Ebaid, M., & Saab, S. (2023) · Gastroenterology report · doi:10.1093/gastro/goae072 · Cited by 8
Shen, L., Chen, J., Gong, R., Lin, Z., Lin, Y.-S., Qiao, X., Hu, Q.-M., Yang, Y., Chen, S., & Chen, G. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155959 · Cited by 8
Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future
Hwang, S. Y., Choi, H., Jeon, W., & Kim, R. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.08.30 · Cited by 8
Kim, S., Lee, S. Y., Cheon, J., Kim, H., Park, Y. G., Lee, J. J. X., Ryu, M., Ryoo, B., Tai, D. W.-M., & Yoo, C. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01103-7 · Cited by 7
“Beyond atezolizumab-bevacizumab, other ICI-based combination therapy, such as dual ICIs combining anti-PD-1/L1 with anti-CTLA4 and the combinations of tyrosine kinase inhibitors and ICIs, have demonstrated promising efficacy in the first-line setting [14–16].”
Marsh‐Wakefield, F., Santhakumar, C., Ferguson, A. L., Ashhurst, T. M., Shin, J., Guan, F. H. X., Shields, N. J., Platt, B. J., Putri, G., Gupta, R., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000540 · Cited by 8
Impact of race, ethnicity, and social determinants on outcomes following immune checkpoint therapy
Nayak, R., Aiello, M., Maldonado, L., Clark, T. Y., Buchwald, Z. S., & Chang, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010116 · Cited by 8
Marzi, L., Mega, A., Turri, C., Gitto, S., Ferro, F., & Spizzo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111676 · Cited by 8
“OS at 36 months was 30.7% and 20.2%, respectively [18].”
BackgroundMethodResultInfluentialComprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice
Terashima, T., Yamashita, T., Arai, K., Takata, N., Hayashi, T., Seki, A., Nakagawa, H., Nio, K., Iida, N., Yamada, S., et al. (2024) · Hepatology International · doi:10.1007/s12072-024-10741-y · Cited by 8
Xiong, X., & Guo, J. J. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01453-0 · Cited by 8
Patel, M. R., Falchook, G. S., Wang, J. S.-Z., Imedio, E. R., Kumar, S., Miah, K., Mugundu, G. M., Jones, S. F., Spigel, D. R., & Hamilton, E. P. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01110-8 · Cited by 8
Marco, L. D., Romanzi, A., Pivetti, A., Maria, N. D., Ravaioli, F., Salati, M., Villa, E., Benedetto, F. D., Magistri, P., Dominici, M., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104607 · Cited by 8
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16871 · Cited by 8
Advancements in immunotherapy for hepatocellular carcinoma
Ascari, S., Chen, R., Vivaldi, C., Stefanini, B., Sinno, A. D., Dalbeni, A., Federico, P., & Tovoli, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2461631 · Cited by 8
Moon, A. M., Kappelman, M. D., Barritt, A. S., Evon, D. M., Sanoff, H. K., & Wagner, L. I. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s347929 · Cited by 9
Möhring, C., Berger, M., Sadeghlar, F., Zhou, X., Zhou, T., Monin, M. B., Shmanko, K., Welland, S., Sinner, F., Schwacha-Eipper, B., et al. (2025) · Cancers · doi:10.3390/cancers17060972 · Cited by 9
Self-citationFortuny, M., García-Calonge, M., Arrabal, Ó., Sanduzzi‐Zamparelli, M., Castaño‐García, A., Cascos, E., Mesa, A., Piedra-Cerezal, A. M., Llarch, N., Iserte, G., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115404 · Cited by 8
Self-citationOsborne, N., Rupani, A. R., Makarov, V., Chan, T. A.-T., & Srivastava, R. M. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2494995 · Cited by 9
“18,19 Both mAbs are under evaluation in clinical trials for a multitude of other cancer types, making it important to further characterize these therapies.”
Ennin, E., Mallepally, N., Ali, M., Shojaie, L., Dewberry, S., Trieu, M., Torres, E. T. R., Zhou, K., Kahn, J. A., Dodge, J. L., et al. (2025) · Liver International · doi:10.1111/liv.70255 · Cited by 8
“Other approved first-line immunotherapy options include atezolizumab–bevaci-zumab and durvalumab–tremelimumab, the latter supported by the HIMALAYA trial [31].”
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy
Fortuny, M., da Fonseca, L. G., Allaire, M., Sánchez, R., Nault, J., Iavarone, M. A., Ridolfo, S., Pascual, S., Jimeno, R., Calvo, M., et al. (2025) · Liver International · doi:10.1111/liv.70264 · Cited by 8
Self-citationOhara, M., Suda, G., Kohya, R., Yasui, Y., Tsuchiya, K., Kurosaki, M., Tani, J., Maekawa, S., Enomoto, N., Chuma, M., et al. (2025) · Hepatology International · doi:10.1007/s12072-025-10875-7 · Cited by 8
Kournoutas, I. A., Marell, P. S., Gile, J. J., Peersen, A. F., Shah, P., VanDommelen, K., Kamath, S. D., Gupta, G., Akce, M., Yang, J. D., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf286 · Cited by 8
Gao, B., Wang, Y., Sun, Z., Tang, H., Cao, Y., Jiang, H., Zhang, W., Xu, Y., Hu, B., Liu, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202511152 · Cited by 8
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis
Salani, F., Ponziani, F. R., Piscaglia, F., Malapelle, U., Daniele, B., Porta, C., Pradelli, L., Fiore, E. D., Masi, G., Rimassa, L., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105879 · Cited by 9
Self-citationChan, S. L., Kudo, M., Sangro, B., Kelley, R. K., Kim, J. H., Pham, B. V., Hong, J. Y., Waldschmidt, D., Marino, D., Lee, J. J. X., et al. (2025) · Liver Cancer · doi:10.1159/000549955 · Cited by 8
Self-citationChen, J., Zhi-Cheng, J. I. N., Zhou, J.-W., Ding, R., Tie, J., Xin, Y., Zhang, L., Huang, M., Zhu, X.-L., Zhou, G.-H., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103766 · Cited by 9
Guiu, B., Bailly, C., Vibert, É., Tlili, G., Mariano‐Goulart, D., Edeline, J., Touchefeu, Y., Durand, E., Blanc, J. F., Chalaye, J., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103884 · Cited by 8
“23,25 This is clinically relevant, as PVT extension is a key determinant of treatment selection, including for SIRT.”
Giuffrida, P., Celsa, C., Antonucci, M., Peri, M., Grassini, M. V., Rancatore, G., Giacchetto, C. M., Cannella, R., Incorvaia, L., Corsini, L. R., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112827 · Cited by 8
“In the recent HIMALAYA trial—a phase III study—a regimen of antiCTLA-4 (cytotoxic T-lymphocyte antigen 4) tremelimumab plus the anti-PD-L1 durvalumab was compared with sorafenib and with durvalumab monotherapy.”
BackgroundResultInfluentialJeschke, M., Ludwig, J. M., Leyh, C., Pabst, K. M., Weber, M., Theysohn, J. M., Lange, C. M., Herrmann, K., Schmidt, H., & Jochheim, L. S. (2023) · Cancers · doi:10.3390/cancers15174274 · Cited by 8
Breitenecker, K., Hedrich, V., Pupp, F., Chen, D., Řezníčková, E., Ortmayr, G., Huber, H., Weber, G., Balcar, L., Pinter, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1238883 · Cited by 8
Hwang, S. Y., Woo, H. Y., Heo, J., Kim, H. J., Park, Y. J., Yi, K. Y., Lee, Y. R., Park, S. Y., Chung, W. J., Jang, B. K., et al. (2024) · Cancers · doi:10.3390/cancers16040838 · Cited by 8
Shimizu, A., Kubota, K., Notake, T., Kitagawa, N., Masuo, H., Yoshizawa, T., Sakai, H., Hayashi, H., Yamazaki, S., & Soejima, Y. (2024) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.12004 · Cited by 8
Primary liver cancer organoids and their application to research and therapy
Zhu, X., Trehan, R., & Xie, C. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.06.002 · Cited by 8
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)
López, C., Calvo, M., Cámara, J. C., García-Paredes, B., Gómez-Martín, C., López, A. M., Pazo-Cid, R., Sastre, J., Yayá, R., & Feliú, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03568-4 · Cited by 8
“In this trial, durvalumab monotherapy was not inferior to sorafenib [51].”
BackgroundImmunotherapy in Gastrointestinal Cancers
Lote, H., & Chau, I. (2024) · Cancer treatment and research · doi:10.1007/978-3-031-61238-1_14 · Cited by 8
Güven, D. C., Erul, E., Şahin, T. K., Dızdar, Ö., Yalçın, Ş., & Şahin, İ. H. (2022) · Future Oncology · doi:10.2217/fon-2022-0642 · Cited by 9
Chami, P., Jarnagin, W. R., Abou‐Alfa, G. K., Harding, J. J., Kim, N., Lin, H., Homsi, M. E., Crane, C. H., & Hajj, C. (2023) · Cancers · doi:10.3390/cancers15061748 · Cited by 8
Self-citationWang, Y., Lau, W. Y., Li, Y., Tian, Y., Lei, Y., Wang, J., & Xia, F. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000652 · Cited by 8
Palmer, M. E., Gile, J. J., Storandt, M. H., Jin, Z., Zemla, T., Tran, N. H., & Mahipal, A. (2023) · Cancers · doi:10.3390/cancers15194867 · Cited by 8
“HIMALAYA is a phase 3 trial that evaluated tremelimumab, a CTLA-4 inhibitor, and durvalumab, a PD-L1 inhibitor, compared to sorafenib as a first-line therapy for HCC and demonstrated an improved median overall survival (mOS) (16.56 months vs. 13.77 months, HR 0.76, 95% CI 0.65–0.92, p = 0.0035) [12].”
BackgroundInfluentialBteich, F., Desai, K., Zhang, C., Kaur, A., Levy, R., Bioh, L., Wang, A. H., Sultana, S., Kaubisch, A., Kinkhabwala, M. M., et al. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s436804 · Cited by 8
“This finding is in line with current data such as the meta-analysis by Won Jin Ho et al as well as the subgroup analysis of the HIMALAYA trial which studied dual immunotherapy, namely durvalumab with tremelimumab, in advanced HCC. 22,31 In both settings, there was no significant difference in response rate or survival…”
BackgroundInfluentialWu, Z., Boen, J., Jindal, S., Basu, S., Bieniosek, M. F., He, S., LaPelusa, M. B., Mayer, A. T., Kaseb, A. O., Zou, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.11.656869 · Cited by 11
“Immunotherapy has proved promising for both early and late stage HCC[8–10], though a significant fraction of HCC patients undergoing treatment fail to respond[1,11,12].”
Kim, J. H., Kim, J. H., Yoon, H., Ko, G., Shin, J. H., Gwon, D. I., Ko, H. K., Chu, H. H., Kim, S. H., Kim, G. H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1072922 · Cited by 7
“This median OS was longer than that observed in patients with advanced HCC treated with systemic treatment in the recent randomized phase III trials (median OS; 15 – 16 months) (20, 21).”
Management of autoimmune and viral hepatitis in immunotherapy: a narrative review
Kuo, L., Kuwelker, S., & Tsai, E. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-23-250 · Cited by 6
Pourbagheri‐Sigaroodi, A., Momeny, M., Rezaei, N., Fallah, F., & Bashash, D. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4098 · Cited by 7
Uchikawa, S., Kawaoka, T., Murakami, S., Miura, R., Shirane, Y., Johira, Y., Kosaka, M., Fujii, Y., Fujino, H., Ono, A., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14104 · Cited by 7
Wang, Q., Yu, J., Sun, X., Li, J., Cao, S., Han, Y.-J., Wang, H., Yang, Z., Li, J., Hu, C., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104522 · Cited by 8
Fujiwara, Y., Kuroda, H., Abe, T., Kakisaka, K., Nakaya, I., Ito, A., Watanabe, T., Yusa, K., Nagasawa, T., Sato, H., et al. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00458-7 · Cited by 6
“The Durva/Treme protocol consisted of tremelimumab (300 mg, 1 dose) plus durvalumab (1500 mg, every 4 weeks) according to the manufacturer’s guidelines [7].”
InfluentialYonemoto, T., Ogasawara, S., Kanogawa, N., Miwa, C., Fujiya, M., Tsuchiya, T., Sawada, M., Akatsuka, T., Izai, R., Yumita, S., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14160 · Cited by 7
Ikeda, M., Morizane, C., Ueno, M., Okusaka, T., Ishii, H., & Furuse, J. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf017 · Cited by 9
“Both the Atezo + Bev [3] and Durva + Treme [4] regimens have outperformed Sora in terms of the overall survival.”
InfluentialSelf-citationNaganuma, A., Kakizaki, S., Hatanaka, T., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14171 · Cited by 7
Self-citationSystemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon’s Perspective
Zhu, X., Zhao, L., Li, B., Cheng, Y., & Sun, H. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s504457 · Cited by 7
“34 The results indicated that compared to sorafenib, the STRIDE regimen presented a significant reduction in risk of death (28%).”
InfluentialGoodsell, K. E., Tao, A. J., & Park, J. O. (2025) · Frontiers in Surgery · doi:10.3389/fsurg.2025.1531852 · Cited by 8
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025
Kumar, K., & Saraswat, V. A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102547 · Cited by 10
Abdelrahim, M., Esmail, A., Kim, R. D., Arora, S. P., Arshad, J., Kournoutas, I. A., O'Donnell, C., Totev, T. I., Tan, A., Mu, F., et al. (2025) · Cancers · doi:10.3390/cancers17111814 · Cited by 7
Zhao, H., Ren, R., Zhang, X., Zhan, M., Cui, J., Zhang, J., Liu, X., Wu, L., Chen, Y., Zhou, Y. J., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1298 · Cited by 7
Cao, F., Wen, C., Wang, Y., Tan, H., Hao, S., Chen, J., Chen, S., Shen, L., Xie, L., Qi, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1602031 · Cited by 10
“However, the study excluded HCC patients with portal vein thrombosis, as these patients typically have a poorer prognosis (12).”
Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions
Philippi, Z., Reddy, K. D., Malik, S., Al-Khalil, Z., & Dbouk, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135994 · Cited by 9
“Durvalumab monotherapy was noninferior to sorafenib (HR 0.86, 95.67% CI, 0.73–1.03) and PFS was similar across all groups [73].”
InfluentialPerri, G., Engstrand, J., Wright, R. D., Bronzwaer, S. F. C., Kroese, T. E., Huang, B., Acidi, B., Vitale, A., Cao, H. S. T., van Hillegersberg, R., et al. (2025) · BJS Open · doi:10.1093/bjsopen/zraf070 · Cited by 10
Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Liver Cancer · doi:10.1159/000547519 · Cited by 7
“The IMbrave150 trial [1] and the HIMALAYA trial [2] have provided evidence demonstrating the superiority of Atez/Bev and Dur/Tre over sorafenib, respectively, leading to their approval as first-line treatments for HCC.”
Self-citationMeyers, B. M., Lim, H. J., Brahmania, M., Liu, D. M., Tam, V. C., McLeod, D., Ramjeesingh, R., Knox, J. J., & Vogel, A. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251357719 · Cited by 9
“…against VEGF (atezolizumab plus bevacizumab) or VEGFR-TKIs (camrelizumab plus apatinib), or dual ICI therapy (durvalumab plus tremeli-mumab) have demonstrated superior outcomes compared to sorafenib in registrational trials 33–36 and have emerged as new standards of care in the advanced setting.”
Self-citationImmune evasion from macrophages by NEAT1-induced CD24 in liver cancer
Tsuchiya, H., Hanaki, T., Sakabe, T., Tokuyasu, N., Nagahara, T., Umekita, Y., Isomoto, H., Fujiwara, Y., & Nanba, D. (2025) · Oncogene · doi:10.1038/s41388-025-03537-3 · Cited by 7
Li, T., Gao, S., Dong, D., Chen, Y., & Li, S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104905 · Cited by 7
Scheiner, B., Lombardi, P., D’Alessio, A., Kim, G., Tafavvoghi, M., Petrenko, O., Goldin, R. D., Fulgenzi, C. A. M., Torkpour, A., Balcar, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010975 · Cited by 7
Self-citationLiu, X., Liu, Z., Zhu, C., Kobayashi, T., Lei, P., Shi, Y., Yuan, D., Wang, J., Li, M., Matsui, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66581-3 · Cited by 9
“trials of combination therapy based on immune checkpoint blockade (ICB)(anti-PD-L1withanti-VEGFintheIMbrave150studyandanti-PD-L1 with anti-CTLA-4 in the HIMALAYA study) have transformed systemic therapy for HCC 8,9 .”
Rider, P., Tutusaus, A., Cuño-Gómiz, C., Savino, F., Marsal, A., Llarch, N., Iserte, G., Colell, A., de Frutos, P. G., Hernáez-Alsina, T., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03632-z · Cited by 7
Yang, J., Dai, Y., & Li, J. (2026) · Oncology Reviews · doi:10.3389/or.2025.1687901 · Cited by 7
“The HIMALAYA trial further revealed that dual immunotherapy with durvalumab (an anti–PD-L1 agent) and tremelimumab (an anti–CTLA-4 agent) achieved a 4-year OS rate of 25.2%, thereby expanding the available treatment armamentarium for HCC (11).”
InfluentialEdeline, J., Meyer, T., Blanc, J., & Raoul, J. (2022) · Cancers · doi:10.3390/cancers14235868 · Cited by 9
Role of radiotherapy and its contribution to immunotherapy in hepatocellular carcinoma
Nahm, W. J., Bhatt, A., & Wu, J. J. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-50 · Cited by 7
Current status of vaccine immunotherapy for gastrointestinal cancers
Suzuki, N., Shindo, Y., Nakajima, M., Tsunedomi, R., & Nagano, H. (2023) · Surgery Today · doi:10.1007/s00595-023-02773-y · Cited by 7
“Moreover, for hepatocellular carcinoma [6], gastric [7], esophageal [8], and some colon cancers [9], it has been shown to be effective in the initial treatment and its availability is being planned.”
Santoro, A., Assénat, E., Yau, T. C. C., Delord, J., Maur, M., Knox, J. J., Cattan, S., Lee, K.-H., Conte, G. D., Springfeld, C., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101021 · Cited by 7
“– 33 Unlike some trials, 5,34,35 the present study has included patients with main portal vein thrombosis.”
BackgroundSelf-citationWang, B., Kuang, B., & Lin, G. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01035-2 · Cited by 7
“Moreover, double immune checkpoint inhibitors (tremelimumab plus durvalumab) did not exhibit better OS (16.4 months) and PFS (3.8 months) compared with the survival outcomes in our analysis [25].”
InfluentialZhang, R., Wang, F., You, Z., Deng, D., He, J., Yan, W., Quan, J., Wang, J., & Yan, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05539-8 · Cited by 8
Insights in Molecular Therapies for Hepatocellular Carcinoma
Heumann, P., Albert, A., Gülow, K., Tümen, D., Müller, M., & Kandulski, A. (2024) · Cancers · doi:10.3390/cancers16101831 · Cited by 10
Non-viral-mediated gene transfer of OX40 ligand for tumor immunotherapy
Rakitina, O. A., Kuzmich, A. I., Si, B., Kondratieva, S. A., Pleshkan, V. V., Zinovyeva, M. V., Didych, D. A., Sass, A. V., Snezhkov, E. V., Kostina, M. B., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410564 · Cited by 7
RAD51 High-Expressed Hepatocellular Carcinomas Are Associated With High Cell Proliferation
Takahashi, K., Yan, L., An, N., Chida, K., Tian, W., Oshi, M., & Takabe, K. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.07.046 · Cited by 7
Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC
Lim, H. Y., Heo, J., Peguero, J. A., Ryoo, B., Decaens, T., Barlési, F., Moehler, M. H., Jehl, G., Eggleton, S. P., Bajars, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001054 · Cited by 7
Han, H., Zhao, Z., He, M., Guan, G., Cao, J., Li, T., Han, B., & Zhang, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1474869 · Cited by 7
“Compared with sorafenib, durvalumab plus tremelimumab showed signi fi cant clinical bene fi ts as a fi rst-line treatment, with a median OS of 16.4 months vs. 13.8 months and an ORR of 20.1% vs. 5.1%, respectively (56).”
InfluentialKomatsu, S., Yano, Y., Ishihara, N., Kido, M., Gon, H., Fukushima, K., Urade, T., Yanagimoto, H., Toyama, H., & Fukumoto, T. (2024) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12893 · Cited by 7
Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go
Sung, P. S., Lee, I. K., Roh, P. R., Kang, M. W., Ahn, J., & Yoon, S. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1028728 · Cited by 7
“According to the recent European Association for the Study of the Liver (EASL) guideline, atezolizumab plus bevacizumab or durvalumab plus tremelimumab administration are the preferred first-line treatment in patients with advanced HCC (4, 10, 11).”
BackgroundMethodImmunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Jeong, S., Shin, W.-Y., & Oh, Y. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1150360 · Cited by 7
“(59) testified tremelimumab (cytotoxic T lymphocyte–associated antigen 4 inhibitor) plus durvalumab (anti–PD-L1) or durvalumab monotherapy versus sorafenib in patients with unresectable HCC, which indicated significant improvement in overall survival after tremelimumab plus durvalumab compared to sorafenib and noninfe…”
BackgroundMizuno, K., Imai, N., Yamamoto, T., Yokoyama, S., Yamamoto, K., Ito, T., Ishizu, Y., Honda, T., Kuzuya, T., Ishigami, M., et al. (2023) · Cancers · doi:10.3390/cancers15102853 · Cited by 7
“This regimen does not include drugs that inhibit VEGF activity, and in the trial, treatment-related proteinuria was not described [13].”
BackgroundUnderstanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective
Chung, A.-C., Nasralla, D., & Quaglia, A. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s382310 · Cited by 8
“respectively, approved as first-line therapeutic options for patients with unresectable HCC after trials showed statistically significant improvements in overall survival.(13,14) Conversely, the efficacy of these immunotherapies in the adjuvant setting for HCC remains unclear.”
BackgroundAllaire, M., Manfrédi, S., Lerosey, L., Ganne‐Carrié, N., & Thabut, D. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102059 · Cited by 7
Liver Cancer: Improving Standard Diagnosis and Therapy
Masuzaki, R. (2023) · Cancers · doi:10.3390/cancers15184602 · Cited by 7
“Recently, a combination of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death ligand 1 (PD-L1) inhibitors, tremelimab and durvalumab, showed better overall survival than sorafenib [10] and was incorporated into unresectable HCC treatment.”
BackgroundKobayashi, S., Fukushima, T., Ueno, M., Chuma, M., Numata, K., Tsuruya, K., Arase, Y., Hirose, S., Kagawa, T., Hattori, N., et al. (2024) · Liver International · doi:10.1111/liv.15825 · Cited by 6
“7 Consequently, ATZ + BEV and STRiDE have been recommended as first-line treatments for advanced HCC, according to the latest treatment guidelines from the American Society of Clinical Oncology, 8 European Society of Medical Oncology 9 and the National Comprehensive Cancer Network.”
MethodImmunotherapy Responses in Viral Hepatitis-Induced HCC: A Systematic Review and Meta-Analysis
Anwar, J., Arslan, H. M., Sarfraz, Z., Shuroog, J., Abdelhakeem, A. A. F., Saeed, A., & Saeed, A. (2024) · Current Oncology · doi:10.3390/curroncol31110532 · Cited by 6
Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma
Hakoda, H., Ichida, A., & Hasegawa, K. (2024) · BioScience Trends · doi:10.5582/bst.2024.01372 · Cited by 6
“A phase III trial, the HIMALAYA trial, was conducted to evaluate combination treatment in patients with unresectable HCC ( 27,30 ).”
Chuang, C.-H., Guo, J., Kato, K., & Hsu, C. (2025) · Esophagus · doi:10.1007/s10388-024-01105-4 · Cited by 6
Mccoon, P. E., Wang, Y., Lai, Z., Zhang, Q., Li, W., Wildsmith, S., Morsli, N., Raja, R. G., Holoweckyj, N., Walker, J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2198 · Cited by 6
Future perspectives on immunotherapy for hepatocellular carcinoma
Chan, L. L., & Chan, S. L. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251323199 · Cited by 7
“33,34 Although a proportion of patients experience immune-mediated adverse events (imAEs), most can be managed and few patients require discontinuation of treatment.”
Self-citationStefanini, B., Fulgenzi, C. A. M., Scheiner, B., Korolewicz, J., Cheon, J., Nishida, N., Ang, C., Marron, T. U., Wu, L. Y., Saeed, A., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s462701 · Cited by 8
Self-citation
Metadata
- Authors
- Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., Rimassa, L., Breder, V., Vasilyev, A., Heurgué, A., Tam, V. C., Mody, K., Thungappa, S. C., Ostapenko, Y., Yau, T., Azevedo, S., Varela, M., Cheng, A.-L., Qin, S., Galle, P. R., Ali, S., Marcovitz, M., Makowsky, M., He, P., Kurland, J. F., Negro, A., & Sangro, B.
- Affiliations
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
- Humanity & Health (CN)
- Kindai University Hospital (JP)
- Chinese University of Hong Kong (HK)
- University of California, San Francisco (US)
- Kyorin University (JP)
- Khon Kaen University (TH)
- Asan Medical Center (KR)
- Cancer Research and Clinical Trials Center, Department of Optimal Therapy, National Cancer Hospital, Hanoi, Vietnam
- Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Humanitas University (IT)
- Russian Cancer Research Center NN Blokhin (RU)
- Department of Oncology, Railway Clinical Hospital, St. Petersburg, Russia
- Department of Hepato-Gastroenterology, Robert-Debré Hospital, Reims, France
- University of Calgary (CA)
- Mayo Clinic (US)
- Sri Venkateshwara Hospital, Bangalore, India
- National Cancer Institute (UA)
- Queen Mary Hospital (CN)
- Unidade de Pesquisa em Oncologia Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Liver Unit, Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias–Obra Social Cajastur, Instituto de Investigación Sanitaria del Principado de Asturias, Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturia, Oviedo, Spain
- National Taiwan University (TW)
- 81th Hospital of PLA (CN)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- AstraZeneca (United States) (US)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- ORCID
- Lau, George
- Kudo, Masatoshi
- Chan, Stephen L.
- Kelley, Robin Kate
- Furuse, Junji
- Sukeepaisarnjaroen, Wattana
- Kang, Yoon-Koo
- Rimassa, Lorenza
- Breder, Valeriy
- Heurgué, Alexandra
- Tam, Vincent C.
- Mody, Kabir
- Yau, Thomas
- Cheng, Ann-Lii
- Qin, Shukui
- Galle, Peter R.
- Marcovitz, Michelle
- He, Philip
- Kurland, John F.
- Negro, Alejandra
- Sangro, Bruno
- Venue
- NEJM Evidence
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-26
- Volume
- 1
- Issue
- 8
- Pages
- EVIDoa2100070-EVIDoa2100070
- ISSN
- 2766-5526 (ISSN-L)
- OpenAlex
- W4281645619
- Cited by
- 1,576
- References
- 23
- Citations by year
- 2026: 356 · 2025: 450 · 2024: 421 · 2023: 284 · 2022: 63
- FWCI
- 181.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- NEJM Evidence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- tremelimumab, durvalumab, hepatocellular carcinoma, unresectable liver cancer, CTLA-4 blockade, PD-L1 blockade, sorafenib, overall survival, non-inferiority, immune checkpoint inhibitors, combination immunotherapy, progression-free survival, treatment-emergent adverse events, immune-related adverse events, non-small cell lung cancer
- MeSH terms
- Antineoplastic Agents, Immunological, Sorafenib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
